APGE - Apogee Therapeutics, Inc.
About Apogee Therapeutics, Inc. (https://www.apogeetherapeutics.com)
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Michael Thomas Henderson | Chief Executive Officer & Director | 1989 | $1,291,500 USD |
| Carl Linden Dambkowski | Chief Medical Officer | 1985 | $855,900 USD |
| Jane Pritchett V. Henderson | Chief Financial Officer | 1966 | $855,900 USD |
| Dan Mulreany | Chief Business Officer | – | – |
| Drew Badger | Senior Vice President and Head of Regulatory Affairs & Toxicology | – | – |
| Emily Cox | Senior VP & Head of People | – | – |
| Matthew Batters | Chief Legal Officer & Corporate Secretary | 1976 | – |
| Mehrak Kiankarimi | Senior Vice President of Program & Portfolio | – | – |
| Monica Forbes | Senior Vice President of Finance | 1976 | – |
| Noel Kurdi | Vice President of Investor Relations | – | – |
| Rebecca Dabora | Chief Development Officer | 1960 | – |
| Wendy Aspden-Curran | Senior Vice President of Clinical Operations | – | – |